Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations 28 pathways may be overcome by NK cell-based immunotherapy. This approach may still be limited by the 29 presence of immunosuppressive myeloid populations. Here we demonstrate that NK cells (haNKs) 30 engineered to express a PD-L1 chimeric antigen receptor (CAR) haNKs killed a panel of human and 31 murine head and neck cancer cells at low effector-to-target ratios in a PD-L1-dependent fashion. 32 Treatment of syngeneic tumors resulted in CD8 and PD-L1-dependent tumor rejection or growth 33 inhibition and a reduction in myeloid cells endogenously expressing high levels of PD-L1. Treatment of 34 xenograft tumors resulted in PD-L1 dependent tumor growth inhibition. PD-L1 CAR haNKs reduced 35 levels of macrophages and other myeloid cells endogenously expressing high PD-L1 in peripheral blood 36 from patients with head and neck cancer. The clinical study of PD-L1 CAR haNKs is warranted. 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 3 Background 53   T cell-based immunotherapy, such as immune checkpoint blockade or adoptive T cell transfer, is   54 limited by the ability of T cells to detect major histocompatibility complex (MHC)-presented antigen by 55 tumor cells. Through selective immune pressure during tumorigenesis and progression and genomic 56 instability, subpopulations of tumor cells acquire mutations that lead to defective type II interferon (IFN) 57 responses and altered antigen processing and presentation (1, 2). The presence of these mutations predicts 58 failure to respond to immune checkpoint blockade and adoptive T cell transfer immunotherapy(3-6).
antibodies for 10 minutes prior to staining with primary conjugated antibodies for 30 minutes. For some 126 experiments, spleen and tumors were harvested from mice and processed into single cell suspensions for 127 flow analysis. Only fresh tissues processed as described (21) were analyzed. Following FcR block, 128 primary conjugated antibodies were applied for 45 minutes. Anti-human PD-L1 (29E.203), MICA/B 6 (6D4), HLA-A/B/C (W6/32), CD45 (H130), CD31 (WM59), CD140a/PDGFR (aR1), CD11b (ICRF44), 130 CD68 (Y1/82A), CD16 (3G8), CD33 (WM53), CD14 (M5E2), CD15 (W6D3), HLA-DR (L243), CD3 131 (SK7), CD4 (OKT4), CD8 (SK1), FoxP3 (206D), CD11c (3.9), CD25 (M-A251) and anti-mouse PD-L1 132 (10F.9G2), CD45.2 (104), CD31 (390), CD140a/PDGFR (APA5), CD11b (M1/70), F4/80 (Bm8), Ly6G 133 (1A8), Ly6C (HK1.4), CD3 (17A2), NK1.1 (PK136), CD4 (GK1.5), CD8 (53-6.7), FoxP3 (FJK-16s), 134 CD11c (N418), CD25 (PC61.5) antibodies were purchased from Biolegend, Thermo or BD Biosciences.
135
Isotype control antibodies and fluorescence-minus-one approaches were used to ensure staining 136 specificity. For some experiments, cells were fixed and permeabilized for intranuclear staining using the 137 FoxP3 transcription factor staining buffer set (eBioscience) per manufacturer recommendations. Dead 138 cells were excluded using non-fixable (Sytox, Thermo) or fixable (Zombie, BioLegend) viability dyes.
139
All analyses were performed on a BD Fortessa analyzer running FACSDiva software and interpreted 140 using FlowJo (vX10.0.7r2).
141
Cancer patient samples 142 Whole peripheral blood from patients with advanced stage HPV-negative head and neck cancer was 143 obtained via venipuncture in green top heparinized tubes under an IRB-approved biospecimen 144 procurement protocol (NIDCD 18-DC-0051, NCT03429036). Leukocytes were enriched using a 40/80% 145 Percoll density gradient (cells suspended in upper 40% layer with 80% underlay, 325xg for 23 minutes at 146 room temperature with slow centrifuge brake and acceleration). haNKs at low effector-to-target ratios (0.5:1 or 1:1) was significantly greater compared to haNKs in the 171 absence of IFNγ pre-treatment of target cells. Pre-treatment of target cells with IFNγ significantly 172 increased killing by PD-L1 CAR haNKs but did not increase killing by haNKs. No clear correlation 173 between HLA class I or MICA/B expression and killing by PD-L1 CAR haNKs or haNKs existed. These 174 data suggested that at matched effector-to-target ratios, PD-L1 CAR haNKs kill multiple human HNSCC 175 targets to a greater degree than haNKs, and that susceptibility to PD-L1 CAR haNK killing can be 176 increased with greater PD-L1 expression following IFNγ pre-treatment of target cells.
177
The ability of PD-L1 CAR haNKs or haNKs to kill HPV negative murine HNSCC cells in the 178 presence or absence of IFNγ pre-treatment was next determined. PD-L1 CAR haNKs killed IFNγ pre-expression of PD-L1 and killing by PD-L1 CAR haNKs, but no increase in killing by haNKs was 184 observed. These data revealed that PD-L1 CAR haNKs also kill murine HNSCC cells to a greater degree 185 than haNKs, and that PD-L1 CAR haNK killing can be increased with IFNγ-induced PD-L1 expression.
186
To determine the relative contribution of direct and PD-L1 CAR-mediated killing of human and 
199
The ability of PD-L1 CAR haNKs to kill murine HNSCC allows the in vivo study of efficacy and 200 changes in immune correlatives in a syngeneic system. Immune-competent mice bearing established 201 (100-200 mm 3 ) MOC1 tumors were treated with irradiated PD-L1 CAR haNKs, and the ability of these 202 cells to induce tumor growth inhibition or changes in peripheral or tumor immune composition was 203 measured. PD-L1 CAR haNKs (1x10 7 ) were administered twice weekly given their short lifespan 204 following irradiation. PD-L1 CAR haNK monotherapy induced tumor rejection in 30% of treated mice and tumor growth inhibition in a subset of remaining mice ( Figure 4A ). Tumor rejection was abrogated in 206 mice bearing PD-L1 knockout MOC1 tumors ( Figure 4B ), but heterogeneous tumor growth inhibition 207 was still observed. IFNγ is a primary driver of PD-L1 expression on MOC1 tumor cells(22). To determine 208 if CD8 T cells serve as a significant source of IFNγ, treatment with PD-L1 CAR haNKs was repeated 209 following CD8 cell depletion. This CD8 depletion abrogated tumor growth inhibition observed with PD-210 L1 CAR haNK treatment ( Figure 4C ). Tumor cell-specific PD-L1 expression was significantly increased 211 after PD-L1 CAR haNKs, and this increase was abrogated in the presence of CD8 depletion ( Figure 4D ).
212
These data suggested that PD-L1 CAR haNKs can induce PD-L1-dependent tumor rejection in a 213 syngeneic murine system, and that CD8 T cells are a primary source of IFNγ driving tumor cell PD-L1 214 expression in this model.
215
Circulating and tumor infiltrating immune cells can express high levels of PD-L1. To determine if 216 treatment of MOC1 tumor bearing mice altered immune constituency, splenic and tumor immune subsets 217 were measured by flow cytometry following PD-L1 CAR haNK administration ( Figure 5A ). In the 218 periphery of tumor bearing mice, PD-L1 was uniformly expressed on macrophages and Ly6G hi 219 neutrophilic myeloid cells to a greater degree compared to other cells types. Quantification of splenic 220 immune cell fractions revealed that macrophages and neutrophilic myeloid cells endogenously expressing 221 high levels of PD-L1 were decreased compared to control following treatment, whereas no changes were 222 observed in other immune subsets ( Figure 5B&C ). In the tumor microenvironment, PD-L1 was expressed 223 to a greater degree on macrophages, neutrophilic and monocytic myeloid cells compared to tumor cells or 224 other immune subsets. Infiltration of MOC1 tumors by adoptively transferred PD-L1 CAR haNKs was 225 verified by flow cytometry (Supplemental Figure 5 ). Quantification of tumor immune infiltration revealed 226 decreased macrophages, neutrophilic and monocytic myeloid cells, increased CD8 and CD4 T-227 lymphocytes, and no change in Tregs or NK cells following treatment ( Figure 5B&D ). To validate these 228 findings in an ex vivo setting, peripheral or tumor leukocytes were isolated from mice bearing MOC1 229 tumors, co-incubated with PD-L1 CAR haNKs and flow cytometry was used to determine immune constituency. Similar to results observed in vivo, immune cell subsets from the periphery and tumor that 231 expressed comparatively greater levels of PD-L1 were reduced following 24 hours of co-incubation with 232 PD-L1 CAR haNKs (Supplemental Figure 6A -D). Cumulatively, these data exhibited that PD-L1 CAR 233 haNKs can mediate reduction of immune cells endogenously expressing high levels of PD-L1 in the 234 periphery and tumor microenvironment of MOC1 tumor-bearing wild-type mice.
235
To determine if adoptive transfer of PD-L1 CAR haNKs could mediate tumor growth inhibition 236 in a xenograft system lacking immunity, treatment was performed in severely immunodeficient NSG mice 237 bearing UMSCC-1 human tumors. Tumor growth inhibition was observed, but no tumors were rejected 238 ( Figure 6A ). Somewhat unexpectedly, tumor growth inhibition following PD-L1 CAR haNK treatment 239 was abrogated in NSG mice bearing PD-L1 knockout UMSCC-1 tumors ( Figure 6B ). Flow cytometry and 240 immunofluorescence were used to verify that tumor cell-specific PD-L1 expression within UMSCC-1 241 tumors was increased following treatment with PD-L1 CAR haNKs (Supplemental Figure 7A&B ). These 242 data demonstrated that PD-L1 CAR haNKs can also mediate PD-L1-dependent tumor growth inhibition 243 in immunodeficient mice bearing human HNSCCs, likely through the ability of PD-L1 CAR haNKs to 244 induce IFNγ-dependent PD-L1 expression on tumor cells.
245
The ability of PD-L1 CAR haNKs to reduce the frequency of immune subsets endogenously 246 expressing high levels of PD-L1 may be an important complementary mechanism of action to tumor cell 247 killing. To explore whether this phenomenon can also be observed in patients with cancer, peripheral 248 leukocytes from patients with advanced stage HPV negative HNSCC were co-incubated ex vivo with PD-249 L1 CAR haNK and changes in immune cell frequency were determined by flow cytometry ( Figure 7A ).
250
In the peripheral blood of HNSCC patients, macrophages expressed the greatest levels of PD-L1, and 251 CD14+ and CD15+ myeloid subsets expressed greater levels of PD-L1 compared to lymphoid or NK 252 cells. PD-L1 high macrophages and CD14+/CD15+ myeloid cell subsets were significantly reduced 253 following 24 hours of co-incubation with PD-L1 CAR haNKs ( Figure 7B&C ). These results validated
Discussion

257
As our understanding of the limitations of T cell-based immunotherapy increases, it is evident 258 that alternative immunotherapy approaches to be used in lieu of or in combination with immune 259 checkpoint blockade or T cell cellular therapies are needed. As NK cells detect and eliminate tumor cells 260 via MHC-and antigen-independent mechanisms, NK cell-based immunotherapy may overcome some 261 mechanisms of resistance to T cell-based immunotherapy, including selection of tumor subclones lacking 262 antigen or harboring antigen processing/presentation defects (reviewed in (23)). The presence of genomic 263 alterations in one or more of these antigen processing and presentation pathways predicts response to all 264 forms of T cell-based immunotherapy including immune checkpoint blockade and adoptive transfer cell 265 therapies(3-6). Most existing data has explored whole tumor biopsies for the presence of one or more of 266 these genomic alterations and correlation to response to immunotherapy. However, high degrees in tumor 267 heterogeneity within epithelial malignancies results in multiple subclones of tumor cells(24). The number 268 of tumor subclones present within an individual tumor that harbors one or more of these genomic 269 alterations is unknown. This may be an important predictor of whom would most benefit from NK cell-270 based immunotherapy as an alternative or adjunct to T cell-based immunotherapy.
271
The development of the NK-92 cell line from a patient with Non-Hodgkin's lymphoma allowed a 272 continuously cultured effector NK cell line to be used as an "off the shelf" cell therapy product(8). Repeat 273 infusions of high doses of NK-92 cells had a promising safety profile and induced clinical benefit in some 274 patients(9, 10). NK-92 cells lack most inhibitory killer immunoglobulin-like receptors (KIRs) but require 275 exogenous IL-2 for proliferation in culture (25, 26) . To overcome this requirement, haNKs, or high-276 affinity NK cells, are NK-92 cells engineered to express endoplasmic reticulum-retained IL-2(11). haNKs 277 have demonstrated the ability to efficiently kill carcinoma cells at low effector-to-target ratios (12, 13) . (15, 16, 30, 31) . PD-L1 expression on myeloid cells is 299 sufficient and may even be required for immunosuppression mediated by PD-pathway signaling(30, 32).
300
We and others have demonstrated that elimination of myeloid cells or inhibition of their trafficking into 301 tumors has little effect as a monotherapy but enhances T cell cell-based immunotherapy when used in 302 combination (33) (34) (35) . A natural extension of the work presented here is to combine PD-L1 CAR haNKs 303 with different T cell or NK cell-based immunotherapies to explore if reduction in myeloid cell 304 populations can enhance responses to other immunotherapies. This treatment approach deserves further 305 study and is ongoing in our and other laboratories.
The decision to introduce a PD-L1 CAR into haNKs was made based upon the known 307 immunosuppressive mechanism of PD-L1 and the possibility that both tumor and PD-L1 positive immune 308 cell subsets would be targeted. CAR expression in haNKs may be advantageous over introduction of 309 CARs into autologous T cells as haNK cells lack expression of a native TCR that could mediate an 310 allogeneic immune reaction such as graft-vs-host disease (36, 37) . This suggests that haNK-based CAR 311 immunotherapy may be useful across populations of patients with cancer and not just in individual 312 patients (reviewed in (38) 731  732  733  734  735  736  737  738  739  740  741  742  743  744  745  746  747  748  749  750  751  752  753  754  755  756 was also assessed by immunofluorescence (B, PD-L1 in green, DAPI nucleus stain in blue).
Supplementary Figure S4 -PD-L1 knockout cells maintained IFN responsiveness but lacked PD-L1 expression
PD-L1 knockout cells were generated via CRISPR/Cas9 gene editing and control or IFN pre-treated UMSCC-1 (A), UMSCC-11A (B) or MOC1 (C) HNSCC tumor cells (20 ng/mL for 24 hours) were assayed for PD-L1 or HLA-A/B/C expression via flow cytometry. **, p<0.01; ***, p<0.001.
Supplemental Figure S6 -PD-L1 CAR haNKs deplete PD-L1 high myeloid cells from the spleen and tumors of MOC1 tumor bearing mice Spleens and tumors from wild-type C57BL/6 mice bearing parental day 14 MOC1 tumors were coincubated with PD-L1 CAR haNKs for 24 hours, then changes in immune composition was assessed via flow cytometry (schema shown in A). B, representative dot plots of myeloid cell subsets from tumors are shown. Baseline cell surface PD-L1 expression on immune cell subsets along with changes in immune cell composition following PD-L1 CAR haNK co-incubation are shown from the spleen (C) and tumor (D) compartments (n=5 spleens or tumors/group). Cell surface markers used to identify immune cell subsets are shown. *, p<0.05; **, p<0.01.
Supplemental Figure S7 -UMSCC-1 tumor cells express greater levels of PD-L1 after a treatment with PD-L1 CAR haNKs
NOD-scid IL2Rgamma null (NSG) mice bearing parental UMSCC-1 tumors were treated with one dose of PD-L1 CAR haNKs (1x10 7 cells IP) or 1xPBS control, and tumor cell PD-L1 expression was determined by flow cytometry (A). Representative histograms shown, and MFI inset into legend. PD-L1 expression was also assessed by immunofluorescence (B, PD-L1 in green, DAPI nucleus stain in blue).
